{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:45:33Z","timestamp":1757591133568},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T00:00:00Z","timestamp":1397088000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s12185-014-1575-1","type":"journal-article","created":{"date-parts":[[2014,4,9]],"date-time":"2014-04-09T11:38:54Z","timestamp":1397043534000},"page":"706-713","source":"Crossref","is-referenced-by-count":6,"title":["Cardiac T2* MRI assessment in patients with thalassaemia major and its effect on the preference of chelation therapy"],"prefix":"10.1007","volume":"99","author":[{"given":"Arzu","family":"Akcay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafer","family":"Salcioglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazim","family":"Oztarhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deniz","family":"Tugcu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonul","family":"Aydogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuray Aktay","family":"Ayaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Bornaun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hulya Sayilan","family":"Sen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferhan","family":"Akici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burhan","family":"Akdana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,10]]},"reference":[{"issue":"1","key":"1575_CR1","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1179\/102453311X13127324303470","volume":"17","author":"Y Aydinok","year":"2012","unstructured":"Aydinok Y. Thalassemia. Hematology. 2012;17(1):S28\u201331.","journal-title":"Hematology"},{"key":"1575_CR2","first-page":"1187","volume":"89","author":"C Borgna-Pignatti","year":"2004","unstructured":"Borgna-Pignatti C, Rugolotto S, De Stafano P, et al. Survival and complications in patients with transfusion and deferoxamine. Haematologica. 2004;89:1187\u201393.","journal-title":"Haematologica"},{"key":"1575_CR3","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/10976640600698155","volume":"8","author":"MA Tanner","year":"2006","unstructured":"Tanner MA, Galanello R, Dessi C, et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson. 2006;8:543\u20137.","journal-title":"J Cardiovasc Magn Reson"},{"key":"1575_CR4","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1161\/CIRCULATIONAHA.109.874487","volume":"120","author":"P Kirk","year":"2009","unstructured":"Kirk P, Raughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120:1961\u20138.","journal-title":"Circulation"},{"key":"1575_CR5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1196\/annals.1345.045","volume":"1054","author":"DJ Pennel","year":"2005","unstructured":"Pennel DJ. T2* magnetic resonance and myocardial iron in thalassemia. Ann NY Acad Sci. 2005;1054:373\u20138.","journal-title":"Ann NY Acad Sci"},{"key":"1575_CR6","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1053\/euhj.2001.2822","volume":"22","author":"LJ Anderson","year":"2001","unstructured":"Anderson LJ, Holden S, Davies B, et al. Cardiovascular T-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171\u20139.","journal-title":"Eur Heart J"},{"key":"1575_CR7","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V106.11.406.406","volume":"106","author":"MA Tanner","year":"2005","unstructured":"Tanner MA, Porter JB, Westwood MA, et al. Myocardial T2* in patients with cardiac failure secondary to iron overload. Blood. 2005;106:406.","journal-title":"Blood."},{"issue":"1","key":"1575_CR8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/jmri.10332","volume":"18","author":"M Westwood","year":"2003","unstructured":"Westwood M, Anderson LJ, Firmin DN, et al. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging. 2003;18(1):33\u20139.","journal-title":"J Magn Reson Imaging"},{"key":"1575_CR9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/asheducation-2011.1.443","volume":"2011","author":"JC Wood","year":"2011","unstructured":"Wood JC. Impact of iron assessment by MRI. Hematol Am Soc Hematol Educ Program. 2011;2011:443\u201350.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"14","key":"1575_CR10","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.110.007641","volume":"123","author":"JP Carpenter","year":"2011","unstructured":"Carpenter JP, He T, Kirk P, et al. On T2* magnetic resonance and cardiac iron. Circulation. 2011;123(14):1519\u201328.","journal-title":"Circulation"},{"key":"1575_CR11","unstructured":"Consensus view on choice or iron chelation therapy in transfusional iron overload for inherited anemias. http:\/\/www.emscg.nhs.uk\/Library\/NUHGuidelinesforironchelationtherapy.pdf . Accessed 3 May 2012."},{"key":"1575_CR12","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(00)02357-6","volume":"355","author":"B Modell","year":"2000","unstructured":"Modell B, Khan M, Darlison M, et al. Survival in beta-thalassemia major in the UK: data from the UK Thalassemia Register. Lancet. 2000;355:2051\u20132.","journal-title":"Lancet"},{"key":"1575_CR13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1196\/annals.1345.006","volume":"1054","author":"C Borgna-Pignatti","year":"2005","unstructured":"Borgna-Pignatti C, Cappellini MD, De Stafano P, et al. Survival and complications in thalassemia. Ann NY Acad Sci. 2005;1054:40\u20137.","journal-title":"Ann NY Acad Sci"},{"key":"1575_CR14","first-page":"10","volume":"25","author":"B Modell","year":"2008","unstructured":"Modell B, Khan M, Darlison M, et al. Improved survival of thalassemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;25:10\u201342.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"1","key":"1575_CR15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3324\/haematol.2009.019042","volume":"96","author":"A Pepe","year":"2011","unstructured":"Pepe A, Meloni A, Capra M, et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica. 2011;96(1):41\u20137.","journal-title":"Haematologica"},{"key":"1575_CR16","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","volume":"107","author":"DJ Pennell","year":"2006","unstructured":"Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738\u201344.","journal-title":"Blood"},{"key":"1575_CR17","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1182\/blood.V112.11.3873.3873","volume":"112","author":"DJ Pennell","year":"2008","unstructured":"Pennell DJ, Porter JB, Capellini DM, et al. Efficacy and safety of Deferasirox (Exjade\u00ae) in reducing kardiyac iron in patients with beta-thalassemia major: results from the cardiac substudy of the EPIC trial. Blood. 2008;112:3873.","journal-title":"Blood."},{"key":"1575_CR18","unstructured":"Ayd\u0131nok Y, Levent E, Bayraktaro\u011flu S, et al. Talasemi major olgular\u0131nda kardiyak demir birikiminin ba\u015flang\u0131\u00e7 ya\u015f\u0131, kardiyak fonksiyonlar, karaci\u011fer demir yo\u011funlu\u011fu ve serum ferritin d\u00fczeyleri ile ili\u015fkisi. Ulusal Pediatrik Hematoloji Kongresi, 2009."},{"key":"1575_CR19","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3324\/haematol.12513","volume":"93","author":"JC Wood","year":"2008","unstructured":"Wood JC, Origa R, Agus A, et al. Onset of cardiac iron loading in pediatric patients with thalassemia major. Haematologica. 2008;93:917\u201320.","journal-title":"Haematologica"},{"key":"1575_CR20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/asheducation-2011.1.451","volume":"2011","author":"JL Kwiatkowski","year":"2011","unstructured":"Kwiatkowski JL. Real-world use iron chelators. Hematol Am Soc Hematol Educ Program. 2011;2011:451\u20138.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"5","key":"1575_CR21","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1182\/blood-2003-06-1919","volume":"103","author":"JC Wood","year":"2004","unstructured":"Wood JC, Tyszka JM, Carson S, et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103(5):1934\u20136.","journal-title":"Blood"},{"key":"1575_CR22","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/MPH.0b013e31820c34ef","volume":"33","author":"Y Aydinok","year":"2011","unstructured":"Aydinok Y, Bayraktaroglu S, Yildiz D, et al. Myocardial iron loading in patients with thalassemia major in Turkey and the potential role of splenectomy in myocardial siderosis. J Pediatr Hematol Oncol. 2011;33:374\u20138.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1575_CR23","unstructured":"Thalassemia International Federation 2008. http:\/\/www.thalassaemia.org.cy\/pdf\/Guidelines_2nd_revised_edition_EN.pdf . Accessed 15 Nov 2011."},{"key":"1575_CR24","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3324\/haematol.12413","volume":"93","author":"E Angelucci","year":"2008","unstructured":"Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica. 2008;93:741\u201352.","journal-title":"Haematologica"},{"key":"1575_CR25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/03630260600642567","volume":"30","author":"A Kolnagou","year":"2006","unstructured":"Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators. Hemoglobin. 2006;30:239\u201349.","journal-title":"Hemoglobin"},{"key":"1575_CR26","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1182\/blood-2009-04-217455","volume":"115","author":"DJ Pennell","year":"2010","unstructured":"Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010;115:2364\u201371.","journal-title":"Blood"},{"key":"1575_CR27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3324\/haematol.2010.031468","volume":"96","author":"DJ Pennell","year":"2011","unstructured":"Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement in myocardial T2* over two years of deferasirox therapy in \u03b2-thalassemia major patients with cardiac iron overload. Haematologica. 2011;96:48\u201354.","journal-title":"Haematologica"},{"key":"1575_CR28","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3324\/haematol.2011.049957","volume":"97","author":"DJ Pennell","year":"2012","unstructured":"Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3\u00a0years leads to continued improvement of myocardial T2* in patients with \u03b2-thalassemia major. Haematologica. 2012;97:842\u20138.","journal-title":"Haematologica"},{"key":"1575_CR29","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1182\/blood.V112.11.3882.3882","volume":"112","author":"JC Wood","year":"2008","unstructured":"Wood JC, Thompson AA, Paley C, et al. Deferasirox (Exjade\u00ae) monotherapy significantly reduces cardiac iron burden in chronically transfused beta-thalassemia patients: an MRI T2* study. Blood. 2008;112:3882.","journal-title":"Blood."},{"key":"1575_CR30","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1161\/CIRCULATIONAHA.106.648790","volume":"115","author":"MA Tanner","year":"2007","unstructured":"Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115:1876\u201384.","journal-title":"Circulation"},{"issue":"18","key":"1575_CR31","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2012-05-370098","volume":"120","author":"AV Hoffbrand","year":"2012","unstructured":"Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood. 2012;120(18):3657\u201369.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1575-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-014-1575-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1575-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T13:35:46Z","timestamp":1597671346000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-014-1575-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,10]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["1575"],"URL":"https:\/\/doi.org\/10.1007\/s12185-014-1575-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,10]]}}}